Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in Stage IV Colorectal Cancer
NCT00912743Phase 2
Key facts
- Status
- Completed
- Start
- May 2009
- Primary completion
- Mar 2012
- Countries
- 1
- Sponsor
- AstraZeneca
- Modality
- Small Molecules
- Drugs
- olaparib
- Conditions
- colorectal cancer (CRC)
01
Overview
Phase 2, open-label trial of olaparib in colorectal cancer (CRC), sponsored by AstraZeneca. Primary endpoint: Objective Response Rate at 35 months. Started May 2009; status: completed.
02
Design
- Study design
- Non-randomizedOpen-label
03
Who it enrols
Patients with stage IV colorectal cancer who progressed after standard chemotherapy, stratified by MSI status.
04
Endpoints
Primary
Objective Response Rate
Secondary
Progression-Free Survival
Beyond the preview
Go deeper on NCT00912743.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00912743.